Biomotion Sciences Warrant
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more
Biomotion Sciences Warrant (SLXNW) - Total Liabilities
Latest total liabilities as of September 2025: $4.64 Million USD
Based on the latest financial reports, Biomotion Sciences Warrant (SLXNW) has total liabilities worth $4.64 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biomotion Sciences Warrant - Total Liabilities Trend (2020–2024)
This chart illustrates how Biomotion Sciences Warrant's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biomotion Sciences Warrant Competitors by Total Liabilities
The table below lists competitors of Biomotion Sciences Warrant ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RAKUTEN
BE:RAK
|
Germany | €23.70 Trillion |
|
VCI Global Limited Ordinary Share
NASDAQ:VCIG
|
USA | $23.42 Million |
|
Picton Property Income Ltd
LSE:PCTN
|
UK | GBX229.33 Million |
|
Temir Corp
PINK:TMRR
|
USA | $765.01K |
|
Filtronic
LSE:FTC
|
UK | GBX14.42 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Biomotion Sciences Warrant's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomotion Sciences Warrant's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomotion Sciences Warrant (2020–2024)
The table below shows the annual total liabilities of Biomotion Sciences Warrant from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.85 Million | -60.42% |
| 2023-12-31 | $17.31 Million | +5.48% |
| 2022-12-31 | $16.41 Million | +3124.89% |
| 2021-12-31 | $508.92K | +69.98% |
| 2020-12-31 | $299.39K | -- |